Addiction

CORRECTION: 2025’s Top-Rated EHR Vendors Across 40 Medical & Surgical Specialties: Black Book Insights Into Innovation and Client-Centric Excellence

Correction: This release has been updated to reflect accurate specialty-focused EHR top ratings. NextGen Healthcare has achieved five specialty-focused EHR...

Ambulatory EHR Excellence: Top Vendors Recognized for Innovation and User Satisfaction in Black Book 2025 User Surveys

Top EHR Vendors Shine in Multiple Specialties: ModMed, NextGen Healthcare, Netsmart, ClinicMind, Epic, and RXNT Lead the Pack TAMPA, FLORIDA...

2025’s Top-Rated EHR Vendors Across 40 Medical & Surgical Specialties: Black Book Insights Into Innovation and Client-Centric Excellence

25 EHR Vendors Recognized Across 40 Physician Specialties, with ModMed, NextGen, Netsmart, ClinicMind, Epic, and RXNT Leading in Multiple Categories...

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing...

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States...

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2...

BRAIN.ONE Brain Fitness Platform Announces Strategic Partnership with Acclaimed Thought Leader Tim Storey and Global Recovery Advocate Darren Prince

ASPEN, Colo., Dec. 17, 2024 /PRNewswire/ -- BRAIN.ONE, a groundbreaking personalized brain fitness platform, is pleased to announce a partnership...

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review...

error: Content is protected !!